Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This commentary examines whether 5α-reductase inhibitors are effective and safe for transfeminine and transmasculine individuals, highlighting the lack of efficacy and safety data in gender diverse populations and suggesting that clinicians discuss potential benefits and risks with patients considering their use.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

This study reported the development of two highly sensitive ELISA assays to detect banned substances finasteride and dutasteride in human urine, offering better sensitivity than existing HPLC/MS/MS methods.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.

This article reviews the management of excessive pre-ejaculate, highlighting case reports where 5-α-reductase inhibitors, such as finasteride and dutasteride, led to symptom resolution in patients reporting distress due to this condition.

This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.

This study found that using nanoporous silica entrapped lipid-drug complexes enhanced the solubility and bioavailability of dutasteride in beagle dogs.

This study explored using a chitosan oligomer coating for topical delivery of dutasteride-loaded nanostructured lipid carriers, aiming to reduce systemic exposure and cytotoxicity.

This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.

This study found that dutasteride affected spinal bone formation in curdlan-treated SKG mice, while DHT treatment reduced osteoblast differentiation in vitro, suggesting that DHT inhibition might unexpectedly increase spinal ankylosis progression in ankylosing spondylitis patients.

This case report describes an atypical postfinasteride syndrome in a patient treated with both dutasteride and finasteride for androgenic alopecia, highlighting its multisystem involvement and irreversible nature.

This article reviews factors influencing hair growth and treatment options for androgenetic alopecia, but it reports no new clinical results on their effectiveness.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

This study found that dutasteride treatment in pregnant mares significantly increased progesterone concentrations but did not alter gestational length or neonatal outcomes.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This article reviews the increasing incidence of frontal fibrosing alopecia since its first description in 1994 and reports no new results.

This study reported that a liquid-liquid extraction method using methyl tert-butyl ether and methylene chloride was most effective for extracting dutasteride and its internal standard from rat plasma.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This study found that patients treated with dutasteride were significantly less likely to experience acute urinary retention and prostate-related surgeries compared to those treated with finasteride.

This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This study evaluated oral dutasteride for male androgenetic alopecia in a real-world setting, reporting that it effectively improved hair conditions in 90% of patients using monotherapy, with a good safety profile, particularly at low doses.

This article reviews frontal fibrosing alopecia, exploring its characteristics, demographics, and associated conditions, and calls for controlled trials due to an increase in worldwide cases; it reports no new findings.

The source does not provide an abstract for this letter to the editor, so specific results regarding the long-term efficacy and safety of dutasteride for male androgenetic alopecia are not reported.